Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression
Open Access
- 14 March 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 109 (8)
Abstract
Background:MITF encodes an oncogenic lineage-specific transcription factor in which a germline mutation (MITFE318K) was identified in human patients predisposed to both nevus formation and, among other tumor types, melanoma. The molecular mechanisms underlying the oncogenic activity of MITFE318K remained uncharacterized. Methods: Here, we compared the SUMOylation status of endogenous MITF by proximity ligation assay in melanocytes isolated from wild-type (n = 3) or E318K (n = 4) MITF donors. We also used a newly generated MitfE318K knock-in (KI) mouse model to assess the role of MitfE318K (n = 7 to 13 mice per group) in tumor development in vivo and performed transcriptomic analysis of the tumors to identify the molecular mechanisms. Finally, using immortalized or normal melanocytes (wild-type or E318K MITF, n = 2 per group), we assessed the role of MITFE318K on the induction of senescence mediated by BRAFV600E. All statistical tests were two-sided. Results: We demonstrated a decrease in endogenous MITF SUMOylation in melanocytes from MITFE318K patients (mean of cells with hypoSUMOylated MITF, MITFE318K vs MITFWT, 94% vs 44%, difference = 50%, 95% CI = 21.8% to 67.2%, P = .004). The MitfE318K mice were slightly hypopigmented (mean melanin content MitfWT vs MitfE318K/+, 0.54 arbitrary units [AU] vs 0.36 AU, difference = −0.18, 95% CI = −0.36 to −0.007, P = .04). We provided genetic evidence that MitfE318K enhances BRafV600E-induced nevus formation in vivo (mean nevus number for MitfE318K, BRafV600E vs MitfWT, BRafV600E, 68 vs 44, difference = 24, 95% CI = 9.1 to 38.9, P = .006). Importantly, although MitfE318K was not sufficient to cooperate with BRafV600E alone in promoting metastatic melanoma, it accelerated tumor formation on a BRafV600E, Pten-deficient background (median survival, MitfE318K/+ = 42 days, 95% CI = 31 to 46 vs MitfWT = 51 days, 95% CI = 50 to 55, P < .001). Transcriptome analysis suggested a decrease in senescence in tumors from MitfE318K mice. We confirmed this hypothesis by in vitro experiments, demonstrating that MitfE318K impaired the ability of human melanocytes to undergo BRAFV600E-induced senescence. Conclusions: We characterized the functions of melanoma-associated MITFE318K mutations. Our results demonstrate that MITFE318K reduces the program of senescence to potentially favor melanoma progression in vivo.Keywords
This publication has 30 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisGenes & Development, 2012
- β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient MelanomasCancer Cell, 2011
- A novel recurrent mutation in MITF predisposes to familial and sporadic melanomaNature, 2011
- Senescent cells develop a PARP-1 and nuclear factor-κB-associated secretome (PNAS)Genes & Development, 2011
- Mechanisms, regulation and consequences of protein SUMOylationBiochemical Journal, 2010
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- β-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma developmentGenes & Development, 2007
- A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumorsGenes & Development, 2007
- Mutations of the BRAF gene in human cancerNature, 2002